Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis
Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis
复制标题
DOI：
10.2215/cjn.11611113
复制
发表时间：
2014-07-07
影响因子：
9.8
通讯作者：
Cooper, Christopher J.
中科院分区：
文献类型：
--
作者：
Evans, Kaleigh L.;Tuttle, Katherine R.;Cooper, Christopher J.
背景与目的肾动脉粥样硬化性狭窄患者可从肾素-血管紧张素抑制剂、血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂中获益，但对其使用的相关因素知之甚少。（ClinicalTrials.gov标识：NCT 00081731）是一项前瞻性、国际、多中心临床试验，随机分配了2005年5月至2010年1月期间接受最佳药物治疗的动脉粥样硬化性肾动脉狭窄受试者接受支架植入术与未接受支架植入术。在基线时，931名随机分配的参与者中有853名提供了药物信息。肾功能测定血清肌酐为基础的eGFR在一个核心laborator.Results随机分组前，在419（49%）的853名参与者中使用了肾素-血管紧张素抑制剂。在CKD患者中，肾素血管紧张素抑制剂的使用较低（eGFR
Background and objectives People with atherosclerotic renal artery stenosis may benefit from renin-angiotensin inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers, but little is known about the factors associated with their use.Design, setting, participants, & measurements The Cardiovascular Outcomes in Renal Atherosclerotic Lesions study (ClinicalTrials.gov identified: NCT00081731) is a prospective, international, multicenter clinical trial that randomly assigned participants with atherosclerotic renal artery stenosis who received optimal medical therapy to stenting versus no stenting from May 2005 through January 2010. At baseline, medication information was available from 853 of 931 randomly assigned participants. Kidney function was measured by serum creatinine based eGFR at a core laboratory.Results Before randomization, renin-angiotensin inhibitors were used in 419 (49%) of the 853 participants. Reninangiotensin inhibitor use was lower in those with CKD (eGFR